-+ 0.00%
-+ 0.00%
-+ 0.00%

Optimi Health Completes MDMA Production for Planned Canadian Phase 3 PTSD Trial

PUBT·10/20/2026 12:32:47
Listen to the news
Optimi Health Completes MDMA Production for Planned Canadian Phase 3 PTSD Trial
  • Optimi Health completed an MDMA production batch sufficient for a proposed Canadian Phase 3 trial, an Israeli trial and Australian commercial supply.
  • The Canadian PTSD trial is expected to begin in 2027, enrolling up to 100 veterans and frontline workers for two MDMA-assisted therapy sessions.
  • Australian import permits are secured, with the next commercial shipment planned before the end of 2026.
  • The Israeli PTSD trial, conducted in partnership with MAPS, has received formal authorization from Israel's Ministry of Health.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Optimi Health Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610200830PRIMZONEFULLFEED9849182) on October 20, 2026, and is solely responsible for the information contained therein.